主治医师，助理教授

专业擅长：

肿瘤核医学，肿瘤诊断及分期，新型放射性探针临床转化研究。

社会兼职：

中国抗癌协会肿瘤核医学专委会委员、

北京医学会核医学分会青年委员会委员

2025-2026年度“北京市医师科学家培养计划”

课题：

以课题负责人身份主持“国家自然科学基金青年项目”及“北京大学肿瘤医院院内基金培优项目”

文章：

1. Zhou X, Yan S, Ma X, et al. Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025;52(7):2343-2354. (Q1, IF:7.6)

2. Cui Y, Zhou X, Song Y, Zhai S, Li N. The Value of PSMA-RADS Version 2.0 in the Assessment of Pulmonary Metastases in Patients With Prostate Cancer and the Improvement of Differential Diagnosis Efficiency by PSMA PET/CT Parameters. Clin Nucl Med. 2024;49(11):e566-e573. doi:10.1097/RLU.0000000000005409 (Q1, IF:9.6)

3. Ma X, Zhou X, Hu B, Li X, Yao M, Li L, Qin X, Li D, Yao Y, Hou X, Liu S, Chen Y, Wang Z, Zhou W, Li N, Zhu H, Jia B, Yang Z. Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3838-3850. doi: 10.1007/s00259-023-06373-3. Epub 2023 Aug 9. PMID: 37555904. (Q1, IF:9.1)

4. Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, Pomper MG, Zhu H, Zhao J, Yang Z, Li N. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2022 Apr;63(4):536-542. doi: 10.2967/jnumed.121.262045. Epub 2021 Jul 29. PMID: 34326125; PMCID: PMC8973283.(Q1, IF:10.057).

5. Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, Pomper MG, Zhu H, Zhao J, Yang Z, Li N. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2022 Apr;63(4):536-542. doi: 10.2967/jnumed.121.262045. Epub 2021 Jul 29. PMID: 34326125; PMCID: PMC8973283.(Q1, IF:10.057).